FDA cleared Otsuka’s Simtriyo (centanafadine) on July 24, 2026, the same day as its own priority-review deadline, making it the first-ever norepinephrine, dopamine, serotonin reuptake inhibitor approved for ADHD. The pill covers patients 6 and older weighing at least 20 kg, backed by four Phase 3 trials showing symptom improvement as early as week one, sustained through six weeks of dosing.
Wall Street cares about one number: $615 million. That’s the peak sales Otsuka has guided to, more than ¥100 billion, for a drug that just became the first approved option in an entirely new class for a large, under-penetrated ADHD market.
The catch sits in the label. Simtriyo carries two boxed warnings: suicidal ideation and behavior in pediatric patients aged 6 to 12, and the abuse and addiction risk that comes with any CNS stimulant mechanism. DEA scheduling is still pending, which means Otsuka can’t sell a single capsule yet. Launch is penciled in for “later this year,” contingent on the DEA assigning a schedule.
That pending schedule is the real trade. Land between the tightly controlled stimulants and the loosely controlled non-stimulants, and Simtriyo differentiates itself instead of blending in. Land too close to Schedule II, and the $615 million math gets harder to hit.
DEA’s scheduling call is the next date on the calendar that actually decides this.
— Sarah Chen